Could a common vitamin speed stroke recovery?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with clinical ischemic stroke able to enroll between 72 hours and 7 days after symptom onset. * Patients age 18-85, inclusive. * NIHSS score of 4-21, inclusive, prior to treatment. * Signed IRB-approved informed consent by patient or authorized representative. Exclusion Criteria: General * Participation in another study with an investigational drug or device. * Women known to be pregnant, lactating, or of childbearing potential with a positive urine beta-HCG. * Patients using niacin within the 7 days previous to their stroke. Safety Related * Unstable angina. * Acute Myocardial infarction. * Concurrent arterial bleeding. * Active peptic ulcer disease. * Platelet count less than 100,000 per microliter. * Internationally Normalized Ratio (INR) greater than 1.3 without use of warfarin. * Concurrent use of bile acid sequestrants (colestipol and cholestyramine) * Baseline systolic blood pressure less than 100 mmHg. * History of significant hepatic dysfunction. * Allergy or hypersensitivity to aspirin. * Concurrent use of amiodarone, gemfibrozil, fibrate or other bile acid resin, cyclosporine, itraconazole, ketaconazole, telithromycin, erythromycin, clarithromycin, HIV protease inhibitors, nefazodone, danazol. * Allergy or hypersensitivity to extended-release niacin. * Allergy or hypersensitivity to statin agents. Potentially Interfering with Outcomes Assessment * Prior history of dementia. * Patients without fixed address or those deemed unlikely to present for follow-up by the investigator. * Patients whose life expectancy is less than 24 weeks. * Pre-stroke modified Rankin score\>2. * Glucose less than 50 mg/dl. * Other serious illness (e.g., severe hepatic, cardiac, or renal failure; or a complex disease that may confound treatment assessment). Imaging Related * Evidence of primary intra-parenchymal hemorrhage on initial neuroimaging study. * Neuroimaging evidence of a nonvascular cause for the neurological symptoms.